Artivion Inc

https://www.prnewswire.com/news-releases/artivion-reports-second-quarter-2024-financial-results-302218271.html https://www.marketscreener.com/quote/stock/ARTIVION-INC-12185/finances/

https://seekingalpha.com/article/4700446-data-driven-growth-fuels-more-upside-for-overlooked-artivion?source=content_type%3Areact%7Csection%3Asummary%7Csection_asset%3Aall_analysis%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1 Chancenreiche Spekulation? Der Chart sieht jedenfalls seit > 1 1/2 Jahren recht gut aus. Gruß cfgi

https://seekingalpha.com/pr/17793971-cryolife-receives-ce-mark-for-on-x-ascending-aortic-prosthesis CryoLife Receives CE Mark for On-X® Ascending Aortic Prosthesis Thu February 27, 2020 4:05 PM|PR Newswire|About: CRY ATLANTA, Feb. 27, 2020 /PRNewswire/ -- CryoLife, Inc. (CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union. The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm. These associated aortic root diseases coexist in as many as 10 percent of all aortic valve replacements.

https://www.marketscreener.com/CRYOLIFE-INC-12185/news/CryoLife-4Q-Earnings-Snapshot-29995691/ CryoLife: 4Q Earnings Snapshot 02/13/2020 | 05:12pm EST KENNESAW, Ga. (AP) _ CryoLife Inc. (CRY) on Thursday reported a fourth-quarter loss of $681,000, after reporting a profit in the same period a year earlier. On a per-share basis, the Kennesaw, Georgia-based company said it had a loss of 2 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 10 cents per share. The biological medical device maker posted revenue of $69.7 million in the period. For the year, the company reported net income of $1.7 million, or 5 cents per share, swinging to a profit in the period. Revenue was reported as $276.2 million. CryoLife expects full-year earnings in the range of 15 cents to 17 cents per share, with revenue in the range of $292 million to $298 million. CryoLife shares have risen 11% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $30.20, declining slightly in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRY at https://www.zacks.com/ap/CRY Automated Insights, source Associated Press News